Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

NCT02988817 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

306

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Cervical Cancer
Endometrial Cancer
Non Small Cell Lung Cancer (NSCLC)
Thyroid Cancer
Melanoma
Sarcoma
Solid Tumors

Interventions

BIOLOGICAL: Enapotamab vedotin (HuMax-AXL-ADC)

Sponsor

Genmab